Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Stock Has Average Target Price of $53.00

Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) have been assigned an average rating of “Moderate Buy” from the ten analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $53.00.

IMCR has been the topic of several research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Immunocore in a report on Thursday, October 15th. Wall Street Zen lowered Immunocore from a “buy” rating to a “hold” rating in a research report on Tuesday, July 28th. HC Wainwright lowered their target price on Immunocore from $100.00 to $80.00 and set a “buy” rating for the company in a report on Tuesday. Mizuho increased their price target on Immunocore from $34.00 to $35.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. Finally, Zacks Research downgraded Immunocore from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 3rd.

Immunocore Stock Up 2.0%

Shares of NASDAQ:IMCR opened at $32.38 on Wednesday. The company has a current ratio of 4.62, a quick ratio of 4.44 and a debt-to-equity ratio of 0.94. Immunocore has a 12 month low of $27.50 and a 12 month high of $40.71. The company has a 50-day moving average price of $31.46 and a 200 day moving average price of $31.70. The company has a market cap of $1.67 billion, a price-to-earnings ratio of -49.81 and a beta of 0.82.

Immunocore (NASDAQ:IMCR) last released its earnings results on Friday, November 6th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.11). The business had revenue of $102.22 million for the quarter, compared to the consensus estimate of $152.09 million. Immunocore had a negative net margin of 7.48% and a negative return on equity of 7.96%. As a group, equities research analysts predict that Immunocore will post -0.04 earnings per share for the current year.

Institutional Trading of Immunocore

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC raised its position in shares of Immunocore by 30.9% in the 1st quarter. Janus Henderson Group PLC now owns 594,712 shares of the company’s stock worth $17,919,000 after acquiring an additional 140,308 shares in the last quarter. Braidwell LP purchased a new position in Immunocore in the second quarter valued at about $16,552,000. Renaissance Technologies LLC grew its stake in Immunocore by 16.4% in the first quarter. Renaissance Technologies LLC now owns 164,000 shares of the company’s stock valued at $4,945,000 after purchasing an additional 23,100 shares during the last quarter. Alps Advisors Inc. raised its holdings in Immunocore by 32.7% in the third quarter. Alps Advisors Inc. now owns 68,246 shares of the company’s stock worth $2,067,000 after purchasing an additional 16,826 shares in the last quarter. Finally, Public Employees Retirement System of Ohio bought a new position in Immunocore in the second quarter worth about $2,145,000. Institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body’s T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach. The company’s marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.